BCL2 and breast adenocarcinoma: However, studies show that Wharton's jelly stem cell (hWJSC) lysates were proven to reduce tumor development when MSCs were used as a therapy, displaying tumor-suppressive effects via enhancing pro-apoptotic Bax and lowering/downregulating anti-apoptotic Bcl-2 and SURVIVIN genes on breast adenocarcinoma, osteosarcoma, and ovarian carcinoma cells [96].